Search

Displaying results 8831 - 8840 of 10000 in total
  1. Drug

    Bexirestrant

    go.drugbank.com/drugs/DB21557
    Experimental

    Bexirestrant is a small molecule drug. Bexirestrant has a monoisotopic molecular weight of 477.19 Da.

  2. Drug

    Zelatriazin

    go.drugbank.com/drugs/DB21647
    Experimental

    Zelatriazin is a small molecule drug. Zelatriazin has a monoisotopic molecular weight of 392.11 Da.

  3. Drug

    Rivasterat

    go.drugbank.com/drugs/DB21668
    Experimental

    Rivasterat is a small molecule drug. Rivasterat has a monoisotopic molecular weight of 626.38 Da.

  4. Drug

    Laroprovstat

    go.drugbank.com/drugs/DB21690
    Investigational

    Laroprovstat is a small molecule drug. Laroprovstat has a monoisotopic molecular weight of 414.16 Da.

  5. Drug

    Lecufexor

    go.drugbank.com/drugs/DB21714
    Experimental

    Lecufexor is a small molecule drug. Lecufexor has a monoisotopic molecular weight of 618.05 Da.

  6. Drug

    Matsupexole

    go.drugbank.com/drugs/DB21715
    Experimental

    Matsupexole is a small molecule drug. Matsupexole has a monoisotopic molecular weight of 446.25 Da.

  7. Drug

    Balinatunfib

    go.drugbank.com/drugs/DB21728
    Investigational

    Balinatunfib is a small molecule drug. Balinatunfib has a monoisotopic molecular weight of 502.19 Da.

  8. Drug

    Rogocekib

    go.drugbank.com/drugs/DB21739
    Investigational

    Rogocekib is a small molecule drug. Rogocekib has a monoisotopic molecular weight of 408.15 Da.

  9. Drug

    Temanogrel

    go.drugbank.com/drugs/DB05227
    Investigational

    APD791 is an oral anti-thrombotic drug candidate being evaluated in a Phase 1 clinical trial by Arena. … APD791 is intended to lower the risk of arterial thrombosis by reducing the amplification of platelet aggregation, arterial constriction and intimal hyperplasia mediated by serotonin.

  10. Drug

    Dabocemagene autoficel

    go.drugbank.com/drugs/DB17878
    Investigational

    Developed by Castle Creek Biosciences Inc., dabocemagene autoficel is being investigated for the treatment of dystrophic epidermolysis bullosa.[L46797] … Dabocemagene autoficel is an _ex vivo_, autologous cell-based gene therapy. It comprises autologous dermal fibroblasts genetically modified to express functional type VII collagen.